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ABSTRACT
p27Kip1 (p27) is a negative regulator of proliferation and a tumor suppressor 
via the inhibition of cyclin-CDK activity in the nucleus. p27 is also involved in 
the regulation of other cellular processes, including transcription by acting as 
a transcriptional co-repressor. Loss of p27 expression is frequently observed in 
pancreatic adenocarcinomas in human and is associated with decreased patient 
survival. Similarly, in a mouse model of K-Ras-driven pancreatic cancer, loss of p27 
accelerates tumor development and shortens survival, suggesting an important role 
for p27 in pancreatic tumorigenesis. Here, we sought to determine how p27 might 
contribute to early events leading to tumor development in the pancreas. We found 
that K-Ras activation in the pancreas causes p27 mislocalization at pre-neoplastic 
stages. Moreover, loss of p27 or expression of a mutant p27 that does not bind cyclin-
CDKs causes the mislocalization of several acinar polarity markers associated with 
metaplasia and induces the nuclear expression of Sox9 and Pdx1 two transcription 
factors involved in acinar-to-ductal metaplasia. Finally, we found that p27 directly 
represses transcription of Sox9, but not that of Pdx1. Thus, our results suggest that 
K-Ras activation, the earliest known event in pancreatic carcinogenesis, may cause 
loss of nuclear p27 expression which results in derepression of Sox9, triggering 
reprogrammation of acinar cells and metaplasia.
INTRODUCTION
During tumorigenesis, deregulated proliferation 
is one of the hallmarks of neoplastic changes due to 
constitutive activation of mitogenic signaling pathways, 
such as Ras, the most frequently mutated oncogene in 
human cancers, and to inactivation of the cells’ growth 
inhibitory barriers like the p53 and Rb pathways [1, 2]. 
Progression through the cell division cycle is controlled by 
the sequential activation of cyclin-CDK complexes. One 
level of regulation of these complexes is provided through 
their interaction with CDK inhibitors (CKIs) [3].
The CKI p27Kip1 (p27) is an important component of 
the Rb pathway by inhibiting cyclin-CDK activity [3, 4]. 
Indeed, as a negative regulator of the cell cycle, p27 plays 
a critical role in establishing and maintaining quiescence, 
as illustrated by the phenotype of p27 knockout mice 
which are approximately 30% larger than their wild-
type littermates due to hyperplasia in most tissues [5-7]. 
In keeping with this role, p27 protein levels are high in 
quiescent cells and decrease during G1 following mitogen 
stimulation [8, 9]. Although p27 levels are regulated at 
the transcriptional and translational levels, proteolytic 
degradation constitutes a major mechanism to control 
p27 expression [10, 11]. Several degradation pathways 
for p27 have been described and the best understood is 
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instigated in late G1 and S phase by CyclinE-CDK2-
mediated phosphorylation of p27 on Thr187, creating a 
recognition site for the Skp2-SCF E3 ubiquitin ligase, 
which ubiquitinates p27 and promotes its proteasomal 
degradation [12-16].
Consistent with its role in growth inhibition, 
p27 is also a tumor suppressor and mice lacking p27 
are predisposed to both spontaneous and induced 
tumorigenesis [5-8, 17-19]. p27 is haplo-insufficient 
for tumor suppression and loss of one Cdkn1b allele 
is sufficient to promote tumor formation [8, 17-19]. 
Decreased expression of nuclear p27 is commonly 
observed in many types of cancers in human and is a 
significant prognostic marker [20, 21]. However, unlike 
canonical tumor suppressors, p27 mutations are rarely 
observed in cancer and p27 is preferentially inactivated 
either via increased proteolytic degradation or exclusion 
from the nucleus [20, 22-25]. In fact, cytoplasmic 
localization of p27 has been associated with poor prognosis 
in several types of malignancies in human suggesting that 
it could participate in the pathogenesis of the disease [4, 
20, 24, 26-29]. In mice, animals expressing a mutant 
form of p27 that cannot bind to cyclin-CDK complexes 
(p27CK-) are more susceptible to both spontaneous and 
induced tumor formation compared to p27 knockout mice, 
suggesting that p27 can act as an oncogene in vivo [19, 30, 
31]. Subcellular localization of p27 is primarily controlled 
via phosphorylation events, with Ser10 phosphorylation 
promoting nuclear export and Thr157 (absent in mice) and 
Thr198 causing the cytoplasmic retention of the protein 
[20]. Activation of several oncogenic pathways results in 
the localization of p27 in the cytoplasm, including Akt, 
S6K1, Pim, and Ras [8, 17, 19, 20, 24, 32-36].
Over the past years, p27 has emerged as a 
multifunctional protein involved in the control of different 
cellular processes independently of CDK regulation, 
including migration and invasion, apoptosis, autophagy, 
progenitor/stem cell fate and specification, cytokinesis 
and transcriptional regulation [4, 37-40]. For instance, 
cytosolic p27 regulates cell migration and invasion by 
preventing the activation of RhoA [33, 38, 41, 42]. In 
transcriptional control, p27 acts as a transcriptional co-
repressor when bound to specific transcription factors such 
as E2F4-p130 and Ets1 by recruiting the co-repressors 
HDAC1 and mSin3A to the promoters [37]. Interestingly, 
p27 could regulate different subsets of genes either in 
a CDK-dependent or -independent manner [37, 43]. 
In this way, p27 was found to play an important role 
in the repression of Sox2 expression during stem cells 
differentiation [44].
Pancreatic ductal adenocarcinoma (PDAC) is a very 
aggressive type of cancer with a median survival of less 
than a year and a 5-year survival rate inferior to 5% [45]. 
PDAC is a prime example of the multistep progression 
in carcinogenesis, both at the morphological and genetic 
levels [46]. PDACs are thought to arise from cells 
undergoing acinar to ductal metaplasia (ADM), a process 
in which acinar cells transdifferentiate into ductal cells, 
and progressively transition to pancreatic intraepithelial 
neoplasias (PanINs) that evolve to ever more dysplastic 
stages to become PDACs [45-51]. Similarly, the mutation 
pattern follows a relatively conserved course: K-Ras 
activation is found in the earliest stages, with concomitant 
activation of EGFR signaling and as preneoplastic 
lesions evolve, they accumulate other mutations, mainly 
inactivation of tumor suppressors, such as p16INK4A, p53, 
SMAD4 and BRCA2 [45, 46, 48, 50]. Murine models 
expressing activated K-Ras remarkably reproduce 
the evolution of the pathology and different stages of 
the human disease [47-51]. Pancreatic inflammation - 
pancreatitis, plays a critical role in promoting the early 
changes leading to PDAC formation and several mouse 
PDAC models have confirmed this hypothesis in vivo 
[47, 48, 52, 53]. During ADM, acinar cells dedifferentiate 
and re-express markers of pancreatic ductal progenitors 
such as Pdx1, Sox9, Hes1 and Hnf1b [51, 52, 54]. In fact, 
Sox9 expression is induced by activated K-Ras in acinar 
cells before metaplastic changes occur and is required for 
PanIN formation in K-RasG12D mice by promoting acinar 
to ductal reprogramming [51]. 
Loss of p27 nuclear expression is a frequent 
occurrence, between 46-70%, in pancreatic 
adenocarcinomas and is associated with poor prognosis 
[55-58]. While a fraction of PDAC exhibit mislocalization 
of p27 in the cytoplasm [56], it is not associated with 
negative prognostic, unlike other types of cancers in 
which cytoplasmic p27 is a marker of decreased survival 
compared to complete loss of the protein [24, 27-29]. In 
addition, deletion of a single p27 allele was sufficient 
to promote tumorigenesis in a K-RasG12D-driven PDAC 
murine model, which was further accelerated when both 
alleles were absent, indicating that p27 inactivation may 
contribute to the development of PDAC [59]. 
Herein, we explored the possible contribution of 
p27 loss in pre-neoplastic changes in the pancreas. We 
found that K-Ras activation in the pancreas causes a 
redistribution of p27 in the cytoplasm of acinar cells. We 
next analyzed pancreata from p27-null and p27CK- mice 
and found that in both lines, there was a mislocalization of 
acinar polarity markers such as Integrin β1 and Munc18 
and re-expression of ductal progenitor markers like 
Pdx1 and Sox9. Furthermore, we found that p27 directly 
participated in the repression of Sox9 expression. Thus, 
our data suggests that loss of nuclear expression of p27 
following K-Ras activation may promote Sox9 expression 
and ductal reprogramming and ADM.
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RESULTS
K-Ras activation in the pancreas causes p27 
mislocalization
Loss of p27 considerably shortens survival of 
mice in a K-Ras-driven PDAC model [59], indicating 
a prominent role for p27 in pancreatic cancer. To probe 
for p27’s role in the pancreas, we first determined p27 
levels and localization in pancreata from ElasK-RasG12V 
mice [47, 48]. Indeed, constitutive activation of N-Ras, 
H-Ras and K-Ras does not cause p27 degradation but was 
reported to induce mislocalization of the protein in the 
cytoplasm in various cell types and in the lung [8, 17, 19, 
34, 35]. In absence of activated K-Ras, p27 is expressed 
exclusively in the nuclei of both acinar and β-islet cells 
when compared to background staining in p27-/- pancreas 
(Figure 1A). On the other hand, p27 localization was 
Figure 1: K-Ras activation causes loss of nuclear p27 localization. Sections of paraffin embedded pancreas were stained for p27 
or H&E. A.-B. Localization of p27 in normal pancreas of p27-/- (n = 3), p27+/+ (n = 3) and ElasK-RasG12V (n = 6) mice. Asterisks indicate 
β-islets. C.-E. H&E and p27 staining of consecutive sections in areas of ElasK-RasG12V pancreas showing either metaplasia C., PanIN-1 D. 
or adenocarcinoma E. Scale bars in all images are 50 μm except in E. were the scale bars are 100 μm in the two top images.
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dramatically affected in ElasK-RasG12V pancreata: p27 
was present in both cytoplasm and nuclei in most acinar 
cells while it remained completely nuclear in β-islet cells 
(Figure 1B), consistent with the Elastase promoter driving 
acinar cell-specific expression of K-RasG12V [47, 48]. In 
the different stages of pancreatic neoplastic progression, 
p27 was also seen in both cytoplasm and nucleus in 
areas of ADM (Figure 1C), PanINs (Figure 1D) and 
adenocarcinomas (Figure 1E). Thus, K-Ras activation 
causes at least partial loss of nuclear p27 in the pancreas, 
even in normal areas of the pancreas, before acinar to 
ductal metaplasia, suggesting that p27 inactivation may 
occur very early during pancreatic carcinogenesis.
Loss of p27 affects acinar cell polarity
To determine if loss of p27 function may contribute 
to early events leading to ADM, we monitored several 
known markers of acinar polarity and ADM in the 
Figure 2: Mislocalization of integrinβ1 and Munc18 in acinar cells of p27CK- and p27-/- pancreas. A.-B. Sections of 
paraffin-embedded pancreas from p27+/+, p27-/- , and p27CK-/CK- mice were stained for the basal markers laminin α2 and Munc18 A. or 
laminin α2 and Integrinβ1 B. DNA was stained with Hoechst. All images were acquired using a 60x objective. In A. the graph displays 
the percentage of p27+/+ (n = 12), p27CK-/CK- (n = 13) and p27-/- (n = 12) mice with milocalized Munc18. In B., the graph displays the 
percentage of p27+/+ (n = 11), p27CK-/CK- (n=12) and p27-/- (n = 17) mice with mislocalized Integrinβ1. Mice were considered positive 
for Integrinβ1or Munc18 mislocalization when several areas with non-basal staining were observed. 
Oncotarget35884www.impactjournals.com/oncotarget
pancreas of p27+/+, p27-/- and p27CK- mice. Pancreatic acini 
are highly polarized structures and their architecture is 
completely remodeled during ADM or pancreatitis. For 
instance, Munc18 is located on baso-lateral membranes 
and acts as an inhibitor of SNARE-mediated membrane 
fusion to direct exocytosis to the apical membranes, 
preventing basal release of digestive enzymes [60-62]. 
During pancreatitis, localization of Munc18 to basal 
membranes is lost [60-62]. Munc18 immunostaining 
revealed that in p27-null mice, Munc18 basal localization 
was much more frequently lost than in p27+/+ pancreata 
(Figure 2A). Interestingly, Munc18 mislocalization was 
also observed in p27CK- pancreata suggesting that the 
phenotype is a consequence of the loss of p27-mediated 
CDK inhibition (Figure 2A). On the other hand, we 
never saw alterations in the localization of the basement 
Figure 3: Expression of Sox9 and Pdx1 in acinar cells of p27CK- and p27-/- pancreas. A.-B. Sections of paraffin-embedded 
pancreas from p27+/+, p27-/- , and p27CK-/CK- mice were stained for E-Cadherin and Sox9 A. or E-Cadherin and Pdx1 B. DNA was stained 
with Hoechst. All images were acquired using a 60x objective. The graphs display the percentage of p27+/+ (n = 15), p27CK-/CK- (n = 19) 
and p27-/- (n = 19) pancreas with Sox9 expression A. and Pdx1 expression B. Mice were considered positive for Sox9 when more than a 
half of the pancreas expressed Sox9. Mice were considered positive for Pdx1 when more than a quarter of the pancreas expressed Pdx1.
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membrane component Laminin α2 (Figure 2).
Similarly, Integrin β1 is important for the 
maintenance of acini structure and pancreas-specific 
knockout of the protein leads to progressive organ 
degeneration similar to pancreatitis [62]. Integrin β1 
immunostaining also showed loss of basal localization in 
a majority of p27-null mice (Figure 2B). However, to our 
surprise this phenotype was not as frequently observed 
in p27CK- pancreata, or with only mild delocalization 
of Integrin β1 which was not counted as positive in 
our quantification (Figure 2B). Interestingly, Ki67 
immunostaining did not show any significant changes in 
cell proliferation in the pancreas of adult p27+/+, p27-/- and 
p27CK- mice (data not shown). Thus, our data indicate that 
loss of p27 promotes the mislocalization of acinar polarity 
markers in the pancreas.
Loss of p27 causes re-expression of pancreatic 
ductal progenitor markers
ADM is a transdifferentiation process thought to 
precede PanIN formation in which acinar cells change 
their morphology to acquire ductal characteristics. This 
reprogrammation is accompanied by the re-expression 
of ductal progenitor markers such as Pdx1, Sox9, Hes1 
and Hnf1b [51, 52, 54]. Sox9 levels were monitored by 
immunostaining and we found elevated expression in 
large areas of most pancreata of both p27-/- and p27CK- 
animals (Figure 3A).Thus our results suggest that loss of 
p27-mediated CDK inhibition is sufficient to allow the re-
expression of Sox9. Similar results were obtained when 
Pdx1 expression was investigated, albeit at a much lower 
incidence (Figure 3B). Pdx1 is abundantly expressed in 
β-islet cells and we did not observe any differences in 
Pdx1 levels in β-islets of p27+/+, p27-/- and p27CK- pancreata 
(Supplemental Figure 1). Altogether, our data suggest 
that loss of p27 promotes changes in polarity marker 
localization and pancreatic ductal progenitor markers 
typically observed in pre-metaplastic states and more 
specifically that the loss of p27-mediated CDK regulation 
is sufficient to promote these changes.
p27 directly participates in the repression of Sox9 
transcription
Sox9 and Pdx1 are transcription factors that 
control an expression program specifying multipotent 
progenitor cell pools [63]. Their expression can drive 
the reprogrammation of differentiated acinar cells into 
primitive ductal progenitors during pancreatitis and in 
the transformation process leading to PDAC development 
[51]. p27 was recently found to act as a transcriptional 
co-repressor by binding to transcription factors such as 
E2F4/p130 and Ets1 and recruiting HDAC1 and mSin3A 
to specific promoters [37, 43, 44]. To determine whether 
p27 may participate in the transcriptional regulation 
of Sox9 and/or Pdx1 expression, we used transcription 
reporter assays in which a destabilized GFP cDNA was 
under the control of the Sox9 or Pdx1 promoter (Figure 
4A). Transfection of increasing amounts of p27 decreased 
Sox9 promoter activity compared to the GAPDH promoter 
(Figure 4B), indicating that p27 represses the Sox9 
promoter. 
Consistent with our immunostaining results showing 
an upregulation of Sox9 in the pancreas of p27CK- mice 
similar to the p27-null, expression of the p27CK- protein 
did not repress Sox9 transcription, indicating that the 
Sox9 promoter is regulated in a CDK-dependent manner 
by p27 and requires the CDK inhibitory function of p27 
(Figure 4C). Therefore, in the context of the regulation 
of Sox9 expression, p27CK- behaves like a null allele. On 
the other hand, similar reporter assays conducted on the 
Pdx1 promoter indicated that p27 does not regulate the 
activity of the Pdx1 promoter (Supplemental Figure 2), 
at least not within the sequence used in our experiments 
corresponding to bp -1187 to -31 from the transcription 
start site.
Finally, to confirm the direct role of p27 in the 
control of Sox9 transcription, we performed chromatin 
immunoprecipitations (ChIP) in various cell lines, 
including the pancreatic adenocarcinoma cell line PANC1, 
using p27 antibodies used previously [37, 43, 44] or 
isotype control antibodies, followed by PCR for the Sox9 
promoter sequence. ChIPs with p27 antibodies indicated 
that p27 is present at the Sox9 promoter, while hardly any 
signal was detected in the control ChIPs (Figure 4D). In 
contrast, in similar experiments, p27 was only marginally 
bound to the Sox2 proximal promoter (-300 to -103 from 
transcription start site) in these cells (Supplemental Figure 
3), consistent with p27 previously reported to regulate 
Sox2 transcription by binding to the SRR2 enhancer 
located 4 kb downstream of the Sox2 coding exon [44]. 
Thus, our results suggest that p27 directly participates in 
the transcriptional repression of Sox9, but not to that of 
Pdx1, providing a potential mechanistic explanation for 
the re-expression of Sox9 in the absence of p27 in the 
pancreas.
DISCUSSION
In the nucleus, p27 acts as a tumor suppressor by 
restraining the activities of cyclin-CDK complexes [3, 4]. 
Clinical studies supports this role of p27 in the pancreas 
as nuclear p27 expression is frequently lost in human 
pancreatic cancer, either by total decrease of protein levels 
or exclusion from the nucleus, and this correlates with 
poor prognosis [55-58]. A K-Ras-driven PDAC model 
in mice also support an important role for p27 in tumor 
suppression in the pancreas since ablation of one or both 
p27 alleles considerably decreased survival of the animals 
[59]. 
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Consistent with previous report indicating that p27 
subcellular localization is regulated by Ras activation 
[8, 17, 19, 34, 35], we found that K-Ras activation 
in the pancreas caused the cytoplasmic localization, 
but not degradation, of p27 in pancreatic acinar cells 
and the different lesions observed during neoplastic 
progression leading to PDAC formation. Since K-Ras 
activation is detected in the earliest stage of pancreatic 
neoplasia [64], p27 mislocalization may also occur very 
early in humans, as suggested by our analysis of murine 
Figure 4: p27 represses transcription of Sox9 in a CDK dependent manner. A. Schematic of the reporter construct used in 
transcription reporter assays. The Sox9 promoter is cloned upstream of destabilized GFP (half-life of approximately 1 h). B.-C. 293 cells 
were co-transfected with the Sox9 reporter construct or a control reporter construct in which the GAPDH promoter is cloned upstream of 
GFP and the indicated amount of p27 B. or p27CK- C. The amount of DNA transfected was normalized using a plasmid encoding β-Gal. 
Fluorescence levels were monitored and quantified using an Incucyte FLR on 25 images in each well. The graphs in B and C represent the 
mean fluorescence intensity of the Sox9 promoter normalized to that of the GAPDH promoter in the same condition from six (p27) and five 
(p27CK-) independent experiments. Data were compared by ANOVA followed by Neuman-Keuls multiple comparison test, ** = p < 0.01. 
D. A chromatin immunoprecipitation (ChIP) analysis was performed to determine if p27 could bind the Sox9 promoter in vivo in various 
cell lines. PCR products using primers specific for the Sox9 promoter were separated on an agarose gel. For each cell line, PCRs were 
performed on a fraction of the input and DNA from ChIPs with anti-p27 or isotype control antibodies.
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pancreata expressing activated K-Ras in the acinar 
compartment. To determine a potential contribution 
of p27 mislocalization in these early events leading to 
tumor formation, we investigated the roles of p27 in the 
pancreas using two mouse models, either lacking p27 
expression, or expressing a mutant form of p27 that lacks 
only the ability to inhibit CDK complexes but still fulfills 
its other functions. We found that loss of p27 promoted 
the mislocalization of acinar polarity markers such as 
Munc18 and Integrin β1 and the re-expression of ductal 
progenitor markers like Sox9 and Pdx1. These events 
have been previously associated with pancreatitis and/
or acinar to ductal metaplasia [51, 52, 54, 60-62]. Sox9 
expression promotes ADM in mice expressing K-RasG12D 
under the control of the Ptf1a promoter and in this model, 
Sox9 expression was detected in acinar cells, preceding 
morphological changes induced by ADM and PanNIN 
formation [51], as we observed in p27 mutant mice. ADM 
was very rarely observed in pancreata from p27-null mice 
up to 12 months of age (data not shown), suggesting that 
loss of p27 (and Sox9 expression) is not sufficient to 
cause ADM. Thus other events such as K-Ras or EGFR 
activation may be essential for ADM. Development of 
pituitary tumors and associated morbidity in p27-/- and 
p27CK- mice precludes the examination of older animals 
[5, 30].
Importantly, p27-null and p27CK- pancreas exhibited 
a similar phenotype (with the exception of Integrin β1 
mislocalization), indicating that the loss of p27-mediated 
CDK inhibition is driving this phenotype. Thus, in the 
pancreas, the p27CK- mutation essentially behaved like a 
null mutation. These immunohistological observations 
were confirmed by the fact that Sox9 transcriptional 
repression by p27 was also mediated in a CDK-dependent 
manner as p27CK- expression failed to repress the Sox9 
promoter. We cannot exclude that p27 may adopt an 
oncogenic role in later stages of PDAC development as 
found in other cells and tissues [19, 30, 31] and it would 
be interesting to test this possibility by crossing p27CK- 
mice into an activated K-Ras PDAC model.
We found that p27 repressed Sox9 transcription 
and associated to the Sox9 promoter in ChIP assays. The 
Sox9 promoter is regulated by E2F and Ets transcription 
factors [65-67], it is therefore likely that p27-mediated 
transcriptional repression of Sox9 is accomplished by 
recruiting HDAC1 and mSin3a to E2F or Ets-bound 
promoter, as previously reported [37, 43, 44]. Interestingly, 
EGFR signaling was recently reported to induce Sox9 
transcription in pancreatic acinar cells by the induction of 
the transcription factor NFATc1 and its association with 
c-Jun thereby promoting ADM [68]. In our experiments, 
Pdx1 transcription was not affected by p27 status and 
an attractive possibility is that Sox9 may promote Pdx1 
expression, as reported recently [69].
Overall, the present study suggests that displacement 
of p27 from the nucleus of pancreatic acinar cells in 
response to K-Ras activation may constitute an early event 
promoting metaplasia, notably through the de-repression 
of Sox9, thereby accelerating tumorigenesis as reported in 
a p27-null/K-RasG12D PDAC model [59]. 
MATERIAL AND METHODS
Plasmids and antibodies
Mouse antibodies against β1 integrin (610468), 
E-cadherin (610182) and Munc18 (610337) were from BD 
-Transduction Laboratories. Rat anti Laminin α2 (6D580) 
(sc-71486) and rabbit anti p27 (C-19) (sc-528) were from 
Santa Cruz Biotechnology. Rabbit anti Sox9 (AB5535) and 
goat anti Pdx1 (06-1385) were from Millipore. Rabbit anti 
p27 (RB-9019) was from Thermo Scientific. Secondary 
antibodies conjugated to Cyanine-2, and -3 were from 
Jackson ImmunoResearch. The pcDNA3.1+hygro β-Gal 
(Invitrogen) and pcDNA3.1+hygro p27 and p27CK- have 
been described previously [38]. Promoter sequences 
for GAPDH (corresponding to bp -669 to +394 from 
transcription start site), Sox9 (corresponding to bp 
-1405 to -153 from transcription start site) and Pdx1 
(corresponding to bp -1187 to -31 from transcription 
start site) were purchased from Origene and cloned into a 
pZsGreen1-DR vector encoding a destabilized mutant of 
GFP (Clontech).
Mice and histology
p27-/- and p27CK-/CK- mice were described previously 
[5, 8, 30]. p27 mouse lines were maintained in a 129S4 
genetic background. ElasK-RasG12V mice, in which the 
Cre recombinase is expressed under a Tet-off Elastase 
promoter, allowing K-RasG12V expression in Elastase 
expressing cells in absence of doxycycline treatment, were 
described previously [47, 48].
Mice were maintained and procedures performed in 
accordance with E.U. and national regulations (protocol 
authorization # 00536.02).
Immunofluorescence and immunohistochemistry
Dissected pancreas were fixed in 10% formalin 
overnight, transferred to 70% ethanol for 24 hours, and 
embedded in paraffin. Paraffin blocks were sectioned at 
5μm thickness for histochemistry or immunostaining. 
Paraffin sections were deparaffinized and either stained 
with hematoxylin and eosin, or used for immunostaining. 
Pancreas sections were rehydrated and antigens were 
unmasked in either sodium citrate (10 mM, pH 6) 
(Sox9/E-Cadherin staining), low pH (H-3300, Vector 
Laboratories) (Pdx1/E-Cadherin staining), high pH (H-
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3301, Vector Laboratories) (p27 RB-9019) or pepsin 
0,5% 5mM HCl (Munc18/Lamininα2 and β1-Integrin/
Lamininα2 staining) solutions in a steamer for 30 min. 
Slides were washed twice in PBS-0.2% Triton X-100 and 
once in PBS. Sections were blocked for 0.5 to 2 h at RT 
in PBS-0.2% Triton X-100, 10% donkey serum, 3% BSA 
solution in a humid chamber. Sections were incubated 
with primary antibodies overnight at 4°C, or 1h at 37°C 
and washed 3 times in PBS - 0.2% Triton X-100. For 
immunofluorescence, sections were then incubated for 
30 min at 37°C with secondary antibodies conjugated to 
Cyanine-2, and -3. Slides were washed three times in PBS, 
and cellular DNA was stained with Hoechst H-33342 at 
0.1 μg/mL in the first wash. Slides were mounted with 
gelvatol (20% glycerol (v/v), 10% polyvinyl alcohol 
(w/v), 70 mM Tris pH 8). For immunohistochemistry, 
sections were then incubated for 30 min with Universal 
ImmPRESS reagent (Vector Laboratories), washed three 
times 5 min in PBS-0.2% Triton X-100 and staining was 
visualized using the chromogen 3’3’-diaminobenzidine 
(ImmPACT DAB, Vector laboratories). Images were 
captured on a Nikon 90i Eclipse microscope using a 
CoolSnap HQ camera (Roeper Scientific) or a DS-Fi1 
camera (Nikon) and the NIS-Br software (Nikon).
Cell culture 
HEK293T, PANC-1, HeLa, A549 and U-2 OS 
cells were grown in Dulbecco’s modified Eagle medium 
(DMEM) containing 0.1mM nonessential amino acids, 2 
μg/mL penicillin/streptomycin, 4.5 g/L D-glucose, 1 mM 
sodium pyruvate, and 2 mM L-glutamine (Sigma) and 
10% fetal bovine serum (Life Technologies).
Reporter assays
HEK293T were seeded in 24-wells plates and co-
transfected by the calcium-phosphate method for 24 h 
with 50 ng of either pZsGreen DA (no promoter, negative 
control), pZsGreen pGAPDH (positive control), pZsGreen 
pSox9 or pZsGreen pPdx1 and with pcDNA3.1 hygro p27 
(0, 100 or 200 ng) or pcDNA3.1 hygro p27CK- (0, 100 or 
200 ng). In all conditions, the amount of pcDNA3.1 hygro 
vector was normalized to 200 ng using the pcDNA3.1 
hygro β-Gal plasmid. After 24 h, medium was changed 
and 12 h later, 25 images per well were captured in 
phase contrast and fluorescence with an Incucyte FLR 
automated microscope (Essen BioScience) equipped 
with a 20x objective. Fluorescence area was quantified 
on each image using the Incucyte software following 
manufacturer’s recommendations and the values were 
normalized with the value of pGAPDH fluorescence area 
in each corresponding condition.
Chromatin Immunoprecipitations
PANC-1, HeLa, A549 and U-2 OS were grown 
to confluence. Medium was replaced by PBS and cells 
were fixed for 10 min by adding Formaldehyde to a 
final concentration of 1% to cross-link protein-DNA 
complexes. The cross-linking was stopped by the addition 
glycine at a final concentration of 0.125 M for 5 min. Cells 
were rinsed twice with cold PBS and scrapped in cold 
PBS with Aprotinin, Bestatin, Leupeptin and Pepstatin A 
at 10 μg/mL. Cells were then pelleted by centrifugation 
at 3000 rpm for 10 min at 4°C and the pellets were lysed 
on ice for 30 min using 200 ul/1.106 cells of lysis buffer 
containing 10 mM Tris-HCl pH 8, 0,25% Triton X-100, 10 
mM EDTA, 0,5 mM EGTA, 10 mM Sodium Butyrate, 20 
mM β-Glycerophosphate, 100 μM sodium orthovanadate 
and Protease inhibitor cocktail (Roche). The lysate was 
then dounce homogenized on ice with 20 strokes to aid 
in nuclei release and subsequent chromatin shearing. 
Cells were pelleted by centrifugation at 3000 rpm for 5 
min at 4°C, the supernatant was discarded and the pellet 
containing genomic DNA and cross-linked proteins was 
then re-suspended in 300 ul/3.106 cells of sonication buffer 
containing 10 mM Tris-HCl pH 8, 100 mM NaCl, 1 mM 
EDTA, 0,5 mM EGTA, 10 mM Sodium Butyrate, 20 mM 
β-Glycerophosphate, 100 μM sodium orthovanadate, 1% 
SDS and Protease inhibitor cocktail (Roche) and incubated 
on ice 10 minutes. Chromatin was sheared into fragments 
between 0.5 kb and 1 kb by sonication for 16 cycles of 
30 sec on/20 sec off at 40% amplitude using a Vibra-cell 
VCX130 Sonicator (Sonics). The sonicated material was 
clarified by centrifugation at 14000 rpm for 10 min at 4°C. 
SDS was discarded and supernatant was transferred to new 
tubes. Chromatin shearing was verified on an aliquot of 
chromatin decrosslinked by digestion with Proteinase-K 
and RNAseA on 1% agarose gel. DNA concentration 
was measured with a NanoDrop spectrophotometer. For 
each IP, 100μg of sonicated chromatin was used, while 
10% of the aliquoted volume was retained for use as 
input control and stored a -80°C. Sonication buffer was 
added to the chromatin to a final volume of 800 μl. The 
Sonication buffer was then converted in RIPA buffer by 
the addition of 80 μl Triton 10%, 23 μl NaCl 5M and 
8 μl Sodium Deoxycholate (DOC) 10%, to each tube. 
Four μg of antibodies (rabbit anti p27 C19 or rabbit 
IgG control antibody) and 20 μl of Magna Chip Protein 
A/G magnetic beads (Millipore) were added per IP and 
incubated overnight on a rotating wheel at 4°C. Samples 
were washed 3 times in low salt buffer (10 mM Tris-
HCl pH 8, 0,1% Triton X-100, 0.1% SDS, 0.1% DOC 
, 140 mM NaCl, 1 mM EDTA, 0,5 mM EGTA, 10 mM 
Sodium Butyrate, 20 mM β-Glycerophosphate and 100 
μM sodium orthovanadate), 3 times in high salt buffer 
(same as low salt buffer with 500mM NaCl), twice with 
LiCl buffer (0.25 M LiCl, 1% NP-40, 1% DOC, 10 mM 
Tris-HCl Ph 8, 1 mM EDTA, 1 mM EGTA, 10 mM 
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Sodium Butyrate and 100 μM sodium orthovanadate) and 
finally twice with Tris-EDTA buffer (TE). Subsequent 
elution and purification of the immunoprecipitated DNA-
proteins complexes was performed with an IPure kit 
(Diagenode) according to manufacturer’s instructions. 
PCR for the Sox9 promoter were performed using 20 ng of 
template DNA with Phusion HotStart II DNA polymerase 
(Thermo Scientific) for 35 cycles (denaturation 98°C 
for 10 sec; annealing 60°C for 10sec; elongation 72°C 
for 15 sec). The primer sequences were: SOX9_F: 5’- 
GCGGAGAGAGCAGTGAAAAG-3’; SOX9_R: 5’- 
CCGGGACTTCCAAGTGTGTA-3’. The 165 bp PCR 
product corresponds to nucleotides -406 to -241 from the 
human Sox9 transcription start site.
Statistical analysis
All statistical analyses were performed using 
Graphpad Prism 5.0 software. Differences between groups 
were considered significant when P  <  0.05. All data were 
compared by a one-way analysis of variance (ANOVA) 
followed by Neuman-Keuls multiple comparison tests.
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